Vor Biopharma Welcomes Oncology Expert to Board of Directors
Company Announcements

Vor Biopharma Welcomes Oncology Expert to Board of Directors

Vor Biopharma (VOR) has shared an update.

Vor Biopharma Inc. has expanded its Board of Directors with the appointment of Fouad Namouni, M.D., as an independent Class II director. Dr. Namouni, with over two decades of experience in oncology and cancer immunotherapy, adds significant expertise to the board. His past leadership roles at Bristol Myers Squibb and Blueprint Medicines Corporation underscore his qualifications. Dr. Namouni will also serve on the Nominating and Corporate Governance Committee and will receive the company’s standard compensation for non-employee directors.

For detailed information about VOR stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyVor Bio price target lowered to $8 from $10 at Oppenheimer
TheFlyVor Bio price target lowered to $14 from $22 at Baird
TipRanks Auto-Generated NewsdeskVor Biopharma Reports Q3 2024 Financial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App